Design, synthesis and biological evaluation of novel acrylamide analogues as inhibitors of BCR-ABL kinase.

Research paper by Shuxin S Li, Zhenglin Z Yao, Yanjin Y Zhao, Wei W Chen, Huijia H Wang, Xianzhao X Kuang, Wenhu W Zhan, Shan S Yao, Shanyou S Yu, Wenxiang W Hu

Indexed on: 14 Jul '12Published on: 14 Jul '12Published in: Bioorganic & Medicinal Chemistry Letters


A series of acrylamide analogues were designed and synthesized from Imatinib and Nilotinib as novel BCR-ABL inhibitors by application of the principle of nonclassical electronic isostere. All new compounds were evaluated for their inhibitory effects on the activity of BCR-ABL kinase and the proliferation of K562 leukemia cancer cells in vitro. The acrylamide analogues in which the substituent in C ring was trifluoromethyl group were identified as highly potent BCR-ABL kinase inhibitors. Compound 13f exhibited an IC(50) value as low as 20.6 nM in ABL kinase inhibition and an IC(50) value of 32.3 nM for antiproliferative activity, about 10.5-fold and 12-fold lower than those of Imatinib respectively. These results suggest that compound 13f is a promising candidate as a novel BCR-ABL kinase inhibitor for further development.

More like this: